The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Open accessAbstract
BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This ADNI clinical characterization paper reports baseline and 12-month clinical, cognitive, and CSF biomarker data for 819 participants: 229 cognitively normal, 398 with MCI, and 192 with mild AD. It shows expected group differences at baseline, a 16.5% 12-month MCI-to-AD progression rate, and baseline CSF Aβ-42 predicting 12-month cognitive change in normal and MCI groups.
Key findings
- At baseline, ADAS-Cog total scores were 6.2 ± 2.9 in controls, 11.5 ± 4.4 in MCI, and 18.6 ± 6.3 in AD (p < 0.001); MCI subjects were most impaired on memory items and only mildly impaired in nonmemory domains.
- Over 12 months, 64 of 398 MCI subjects progressed to AD, a rate of 16.5% (95% CI 11.9%–20.5%); normal controls progressed to MCI at an estimated 1.4% (95% CI 0%–3.2%).
- ADAS-Cog 12-month change was −0.5 ± 3.0 in controls, 1.1 ± 4.4 in MCI, and 4.3 ± 6.6 in AD (p < 0.001).
- Baseline CSF Aβ-42 decreased across groups (controls 206 ± 5, MCI 164 ± 4, AD 143 ± 4 pg/mL; p < 0.001), and higher baseline Aβ-42 was associated with better ADAS-Cog performance and smaller 12-month change in normal subjects and MCI.
Methods
- Multicenter ADNI cohort of 819 subjects aged 55–90 enrolled at baseline and classified as cognitively normal, MCI, or mild AD using standard clinical, cognitive, and functional criteria; subjects were followed for 12 months with cognitive and functional measures, MRI/PET in subsets, and lumbar puncture in a minimum of 20% per site.
- Baseline group comparisons used nonparametric tests (Kruskal-Wallis) with Hochberg multiple comparisons and exact tests for proportions; 12-month change was summarized as conversion proportion, baseline-to-12-month mean or percent difference, and rate per year from mixed-effects regression models.
- Annual conversion rates were estimated using a hybrid interval-censored method; CSF Aβ-42 was related to diagnosis, ADAS-Cog performance, and 12-month ADAS-Cog change.
Limitations
- The paper states that a 12-month change period is not sufficient to draw conclusions about the likelihood of clinical change, and that the ADNI cohort likely does not represent “typical” community subjects because participants were more highly educated, mostly white, and had a high proportion of APOE4 carriers in the MCI and AD groups.
- The paper also states that the MCI criteria required a stringent degree of memory impairment, so these subjects were likely further along the clinical spectrum and more likely to progress than less-impaired MCI subjects.
- Evident from the text: CSF analyses were limited to subsets (baseline n = 114 controls, 199 MCI, 102 AD), and some subjects lacked 12-month follow-up diagnoses (17 controls and 41 MCI subjects), which limits interpretation of conversion and biomarker results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Own result · 8 Sources not found · 8 Own interpretation · 5 No basis given · 3 Not checked yet · 3 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“successfully predicted the 12-month change in cognitive measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but they looked more like the AD group for change in digit span, category fluency, and trail making”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonmemory cognitive measures were only minimally impaired in the subjects with MCI.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“The neuropsychological battery indicated that, in general, subjects with MCI were more impaired than controls on the memory items and were only mildly impaired in nonmemory domains (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The sub-jects with AD were impaired in virtually all of the cognitive areas tested.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline CSF measures of A-42 separated the 3 groups as expected”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The next greatest area of impairment for the subjects with MCI resulted from the executive function domain.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI also remained relatively stable as a group, and the subjects with mild AD showed a decline on most of these measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The interaction of A-42 and time also had a significant effect on ADAS-Cog scores in subjects with MCI ( p ϭ 0.00), but not in normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CDR sum of the boxes essentially did not change in the normal control group (0.1) and increased by approximately 0.7 points in the subjects with MCI and 1.5 points in the subjects with AD ( p Ͻ 0.001).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the normal group stayed nearly the same, and the AD group worsened significantly compared to the normal controls.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and more like the normal controls for the clock test and global CDR.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, subjects with MCI had a mean total Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score of 11.5, while the normal control subjects had a score of 6.2 and the subjects with mild AD had a score of 18.7 ( p Ͻ 0.001, table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cholinesterase inhibitors-normal controls 0%, subjects with MCI 43.7%, subjects with AD 84.9%”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 819 subjects were recruited and received a baseline evaluation as part of the ADNI study.”
- Also stated in: § RESULTS Baseline characteristics. · plain
“There were 229 normal control subjects, 398 subjects with MCI, and 192 subjects with mild AD enrolled.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated premorbid verbal IQ of these subjects was quite high, at almost 120 for the normal control subjects, 116 for the subjects with MCI, and 114 for the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedgedn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001, with normal controls performing best, subjects with AD worst, and subjects with MCI in the middle.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MCI group was more variable; in most cases they worsened more than the normal group but not as much as the AD group”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately 50% of the subjects with MCI were on antidementia therapies.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most of the subjects in the study were white, and this was approximately equivalent across the groups.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in table 2, the mean age of the 3 groups was equivalent at approximately 75 years.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there were more men than women in the MCI group (64.6% men vs 35.4% women).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There was somewhat less variability on the global measures, while some of the individual neuropsychological tests such as the AVLT showed considerable variability among the subjects despite relatively modest mean group changes.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CSF A-42 levels were assessed at baseline and were correlated with clinical diagnoses, performance on the ADAS-Cog, and changes in performance on the ADAS-Cog over 1 year (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Delayed recall improved by 5.3% in the normal control group and declined by 4.8% in the subjects with MCI and 7.2% in the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“As such, the baseline characteristics of the subjects indicated that the 3 groups were generally well educated, intelligent, and mostly white, and perform in a fashion similar to subjects recruited for typical clinical trials.[25][26][27][28]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim have been checked yet.
In the paper
“They tend to be more highly educated and the proportion of APOE4 carriers was quite high in the MCI and AD groups but is consistent with subjects recruited for clinical trials.25”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the memory measures such as the AVLT, there was virtually no change across 12 months in learning in the normal control group with a decreased learning of 1.3 items in the subjects with MCI and 3.7 fewer items learned in the AD group.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An additional 8 subjects with MCI reverted to a normal classification over that interval, and 41 did not have a follow-up diagnosis.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“may allow detection of the neurodegenerative process at an earlier point in the spectrum”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [6]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [8]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All hypothesis tests were 2-sided at level 0.05, and models were validated both graphically and analytically.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Data analysis.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Most investigators believe that Alzheimer disease (AD) is a slowly evolving process that likely begins years to decades before the clinical symptoms are manifest.1”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [1]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A 12month change period is not a sufficient amount of time to draw conclusions regarding the likelihood of clinical change.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“has been a target for clinical trials.[2][3][4][5]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The diagnostic conversions over the 12-month period must be viewed with some caution.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This might be a useful technique to reduce the numbers of subjects used in clinical trials to detect a clinical effect of therapeutic interventions.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Mild cognitive impairment (MCI) represents an attempt to characterize subjects at an early clinical phase”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
The paper relies on this without support.
The expected 12-month progression rate for MCI was approximately 16.5% per year.
“The 12-month progression rate of MCI was as predicted”
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
The paper relies on this without support.
The baseline characteristics observed in the recruited cohorts matched the characteristics anticipated for normal, MCI, and AD cohorts.
“The Alzheimer's DiseaseNeuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics.”
The paper relies on this without support.
The MCI subjects have an underlying Alzheimer's disease process that drives clinical progression.
“As such, these subjects were likely further down the clinical spectrum with respect to the underlying AD process such that they would be more likely to progress than subjects with less impairment in the MCI spectrum.”
The paper relies on this without support.
CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another issue is that the vast majority of data from PET and CSF are from selected participants recruited through tertiary care dementia centers [176].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Among the 398 subjects with MCI at baseline, 64 progressed to AD at 12 months”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Table 5 Baseline measures on subjects according to progression status at 1 year Assortment variable Nonprogressors, mean ؎ SD (n ؍ 329) Progressors, mean ؎ SD (n ؍ 69)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“the subjects with mild AD had a score of 18.7”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“ADAS-Cog total 6.2 Ϯ 2.9 11.5 Ϯ 4.4 18.1 18.6 Ϯ 6.3 14.0 Ͻ0.001 a, b, c”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“subjects with MCI (r ϭ Ϫ0.22; 95% CI Ϫ0.035 to Ϫ0.08)”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“95% CI Ϫ0.035 to Ϫ0.08”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“GDS Score 0.8 Ϯ 1.1 1.6 Ϯ 1.4 7.3 1.7 Ϯ 1.4 0.6 Ͻ0.001 a, b”
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Self-citationRandom-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationThe Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Gauthier, S. G., Reisberg, ., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094
Self-citationL’examen Clinique en Psychologie
Rubé, P. (1959) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1959.13.4.989 · Cited by 3,299
Cited by
Sorted by citations
Items 1,301–1,400 of 2,570
Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch
Brown, C. A., Mundada, N. S., Cousins, K. A. Q., Sadeghpour, N., Lyu, X., McGrew, E., Korecka, M., Chen‐Plotkin, A. S., Xie, L., Wisse, L. E. M., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.4974 · Cited by 15
Self-citationCerebrospinal fluid β-amyloid1–42 correlates with rate of progression in Alzheimer’s disease
Vlachos, G. S., Paraskevas, G. P., Naoumis, D., & Kapaki, E. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0798-7 · Cited by 8
O’Bryant, S. E., for the HABS-HD Study Team, Petersen, M. E., Hall, J. R., Johnson, L. A., Barber, R. C., Phillips, N., Braskie, M. N., Yaffe, K. S., Rissman, R. A., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220300 · Cited by 8
“For example, approximately 90% of participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [2] and over 80% of the participants in the NIA-funded Alzheimer’s Disease Centers [3] are non-Hispanic white.”
Self-citationFully Connected Multi-Kernel Convolutional Neural Network Based on Alzheimer’s Disease Diagnosis
Deng, L., Initiative, A. D. N., & Wang, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220519 · Cited by 8
Shankar, V. G., Sisodia, D. S., & Chandrakar, P. (2023) · Computational Intelligence · doi:10.1111/coin.12594 · Cited by 9
Balance Measures Derived from Insole Sensor Differentiate Prodromal Dementia with Lewy Bodies
Kobayashi, M., Yamada, Y., Shinakwa, K., Nemoto, M., Ota, M., Nemoto, K., & Arai, T. (2023) · IEEE International Conference on Digital Health (ICDH) · doi:10.1109/icdh60066.2023.00014 · Cited by 8
“'s clinical diagnosis criteria for probable or possible MCI-LB [5], while MCI-AD was assessed with the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria for MCI [19] and the AD Neuroimaging Initiative (ADNI) criteria for MCI [20].”
MethodKuroda, Y., Goto, A., Sugimoto, T., Fujita, K., Uchida, K., Matsumoto, N., Shimada, H., Ohtsuka, R. Y., Yamada, M., Fujiwara, Y., et al. (2023) · Health Expectations · doi:10.1111/hex.13870 · Cited by 8
Kuroda, Y., Fujita, K., Sugimoto, T., Uchida, K., Shimazu, T., Saito, J., Arai, H., & Sakurai, T. (2023) · Archives of Public Health · doi:10.1186/s13690-023-01205-0 · Cited by 9
A Review on the Use of Modern Computational Methods in Alzheimer’s Disease-Detection and Prediction
De, A., Mishra, T. K., Saraf, S., Tripathy, B. K., & Reddy, S. S. (2023) · Current Alzheimer Research · doi:10.2174/0115672050301514240307071217 · Cited by 8
Zeng, Q., Wang, Y., Wang, S., Luo, X., Li, K., Xu, X., Liu, X., Hong, L., Li, J., Li, Z., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01434-7 · Cited by 8
Sertkaya, M. E., Ergen, B., Türkoğlu, M., & Tonkal, Ö. (2024) · International Journal of Imaging Systems and Technology · doi:10.1002/ima.23079 · Cited by 10
“52 This dataset consists of 5154 MRI images including AD, normal, and mild cognitive impairment categories.”
BackgroundSun, J., Han, J. J., & Chen, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-78712-9 · Cited by 8
Zhang, J., Lyu, Y., Yu, X., Zhang, L., Cao, C., Chen, T., Chen, M., Zhuang, Y., Liu, T., & Zhu, D. (2025) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi60581.2025.10980922 · Cited by 9
Population substructure in Cache County, Utah: the Cache County study
Sharp, A. R., Ridge, P. G., Bailey, M. H., Boehme, K. L., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., Kauwe, J. S., & (ADNI), A. D. N. I. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-s7-s8 · Cited by 6
Alzheimer’s Disease Biomarkers Have Distinct Associations with Specific Hippocampal Subfield Volumes
Müller‐Ehrenberg, L., Initiative, A. D. N., Riphagen, J. M., Verhey, F. R. J., Sack, A. T., & Jacobs, H. I. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180676 · Cited by 9
“Diagnostic procedure, clinical characterization, CSF biomarker and imaging acquisition, and cognitive testing procedures for ADNI are described extensively elsewhere [23].”
MethodBenefit of phonemic cueing on confrontation naming in Alzheimer's disease
Cerbone, B., Massman, P., Woods, S., & York, M. (2020) · Clinical Neuropsychologist · doi:10.1080/13854046.2019.1607904 · Cited by 6
CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors
Pappas, C., Klinedinst, B., Le, S. T., Wang, Q., Larsen, B. A., McLimans, K., Lockhart, S., Allenspach‐Jorn, K., Mochel, J., & Willette, A. (2020) · Alzheimer's & Dementia · doi:10.1002/trc2.12080 · Cited by 7
Fader, K. A., Zhang, J., Menetski, J. P., Thadhani, R., Antman, E. M., Friedman, G. S., Ramaiah, S. K., & Vaidya, V. S. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000204 · Cited by 9
Network edge entropy decomposition with spin statistics
Wang, J., Wilson, R. C., & Hancock, E. R. (2021) · Pattern Recognition · doi:10.1016/j.patcog.2021.108040 · Cited by 9
Lu, P., & Colliot, O. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3100918 · Cited by 8
Quek, Y., Fung, Y. L., Cheung, M. W. ‐., Vogrin, S. J., Collins, S. J., & Bowden, S. C. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28037 · Cited by 8
Diagnostic Utility of Hippocampal Volumetric Data in a Memory Disorder Clinic Setting
Ruchinskas, R., Nguyen, T., Womack, K., Khera, A., Yu, F. F., & Kelley, B. J. (2022) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000295 · Cited by 8
Yang, Z., Caldwell, J., Cummings, J. L., Ritter, A. R., Kinney, J. W., Cordes, D., & (ADNI), T. A. D. N. I. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.804168 · Cited by 8
“In this study, we focused on age-related effects on caudate function by analyzing resting-state functional magnetic resonance imaging (fMRI) data from subjects with normal cognition and subjects with MCI from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) project (18).”
MethodNomograms of human hippocampal volume shifted by polygenic scores
Janahi, M., Aksman, L., Schott, J. M., Mokrab, Y., Altmann, A., & Initiative, O. B. O. F. T. A. D. N. (2022) · eLife · doi:10.7554/elife.78232 · Cited by 8
He, C.-Y., Wang, Z.-T., Shen, Y., Shi, A., Li, H., Chen, D., Zeng, G., Tan, C., Yu, J., Zeng, F., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13965 · Cited by 7
Shi, X., Zhong, X., Zhou, H., Zhou, N., Hu, Y., Ning, Y., & Initiative, A. D. N. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.961842 · Cited by 8
Sible, I. J., Nation, D. A., & Initiative, T. A. D. N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221103 · Cited by 8
“Criteria for MCI were as follows [22]: sub-jectivememorycomplaint;MMSEscoresbetween24 and 30 (inclusive); global Clinical Dementia Rating scale score of 0.5; scores on delayed recall of Story A of the Wechsler Memory Scale Revised Logical Memory II subtest that are below expected performance based…”
InfluentialA Review of AI techniques using MRI Brain Images for Alzheimer's disease detection
Ali, E. H., Sadek, S., & Makki, Z. F. (2023) · International Conference on Advances in Computational Tools for Engineering Applications · doi:10.1109/actea58025.2023.10194002 · Cited by 8
Relative contributions of biomarkers in Alzheimer’s disease
Haight, T. J., & Jagust, W. (2012) · Annals of Epidemiology · doi:10.1016/j.annepidem.2012.09.004 · Cited by 8
Self-citationThe impact of GAB2 genetic variations on cerebrospinal fluid markers in Alzheimer’s disease
Initiative, A. D. N., Chen, X., Guo, R.-R., Cao, X., Tan, L., & Tan, L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.11 · Cited by 8
Abbate, C., Trimarchi, P. D., Inglese, S., Gallucci, A., Tomasini, E., Bagarolo, R., & Giunco, F. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00229 · Cited by 9
Semantic Description of Data Mining Datasets: An Ontology-Based Annotation Schema
Kostovska, A., Džeroski, S., & Panov, P. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-61527-7_10 · Cited by 8
Almubark, I., Alsegehy, S., Jiang, X., & Chang, L. (2020) · IEEE Conference on Big Data and Analytics (ICBDA) · doi:10.1109/icbda50157.2020.9289741 · Cited by 8
“For more details, the readers may refer to [10].”
BackgroundPost Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials
Kennedy, R., Cutter, G., Wang, G., & Schneider, L. S. S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150847 · Cited by 8
Biological Markers and Alzheimer Disease: A Canadian Perspective
Schipper, H. M. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/978182 · Cited by 8
Automated triaging of head MRI examinations using convolutional neural networksPreprint
Wood, D. A., Wood, D. A., Kafiabadi, S., Busaidi, A. A., Guilhem, E., Montvila, A., Agarwal, S., Lynch, J., Townend, M., Barker, G. J., et al. (2022) · doi:10.22541/au.166636171.19660184/v1 · Cited by 8
Shand, C., Markiewicz, P. J., Cash, D. M., Alexander, D. C., Donohue, M., Barkhof, F., Oxtoby, N. P., & Initiative, T. A. D. N. (2023) · medRxiv · doi:10.1101/2023.02.07.23285572 · Cited by 10
Self-citationRobust parametric modeling of Alzheimer’s disease progression
Ghazi, M. M., Nielsen, M., Pai, A., Marc Modat, A., Cardoso, M. J., Sebastien Ourselin, A., & Sørensen, L. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117460 · Cited by 32
“…describe the biomarker trajectories, and they are applied to AD progression modeling of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) ( Petersen et al., 2010 ) and the National Alzheimers Coordinating Center (NACC) ( Beekly et al., 2007 ) data using volumetric MRI biomarkers, CSF and…”
MethodDrouin, S. M., Initiative, A. D. N., McFall, G. P., Potvin, O., Bellec, P., Masellis, M., Duchesne, S., & Dixon, R. A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215289 · Cited by 7
“Individuals were considered cognitively unimpaired at baseline if they: 1) had no memory complaints, 2) scored between 24–30 on the MMSE, 3) had a Clinical Dementia Rating (CDR) score of 0, and 4) scored equal to or above a cut-off based on years of education (3, 5, or 9 for 0–7, 8–15, and 16 or more) on the Logical M…”
MethodCharacterization of Depressive Symptoms in Dementia and Examination of Possible Risk Factors
Sinclair, L. I., Lawton, M., Palmer, J. C., Initiative, A. D. N., & Ballard, C. G. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-239000 · Cited by 6
Association Between False Memories and Delusions in Alzheimer Disease
McLachlan, E., Ocal, D., Burgess, N., Reeves, S., Howard, R. J., Initiative, A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1012 · Cited by 7
Self-citationGuevara, J. E., Kurniadi, N. E., & Duff, K. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230160 · Cited by 7
“These results would appear to augment existing studies in research cohorts [50, 51] in our understanding of cognitive change in MCI.”
Normative modeling for clinical neuroscience
Marquand, A. F., Rutherford, S. E., & Wolfers, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13480-7.00014-4 · Cited by 7
Cirincione, A., Lynch, K. M., Bennett, J., Choupan, J., Varghese, B. A., Sheikh‐Bahaei, N., & Pandey, G. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36728 · Cited by 7
“The multimodal data used in our study were from the TADPOLE Challenge [24], which were derived in turn from the ADNI 1, 2, and GO studies [12,25,26].”
Cytokine dysregulation in amnestic mild cognitive impairment
Tran-Chi, V.-L., Maes, M. H. J., Nantachai, G., Hemrungrojn, S., Solmi, M., Stoyanov, D., Stoyanova, K., & Tunvirachaisakul, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-73099-z · Cited by 7
Schaefer, R., Ayvaz, A., Hoffman, C. R., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.70051 · Cited by 7
Dementia risk scores, apolipoprotein E, and risk of Alzheimer's disease: One size does not fit all
Andrews, S. J., Boeriu, A. I., Belloy, M. E., Renton, A. E., Fulton‐Howard, B., Brenowitz, W. D., Yaffe, K. S., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14300 · Cited by 6
Pan, N., Liu, S., Ge, X., Zheng, Y., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251314785 · Cited by 7
IRMA: Machine learning-based harmonization of $$^{18}$$F-FDG PET brain scans in multi-center studies
Lövdal, S., van Veen, R., Carli, G., Renken, R. J., Shiner, T., Bregman, N., Orad, R. I., Arnaldi, D., Orso, B., Morbelli, S. D., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07114-4 · Cited by 7
Leveraging mHealth wearables for managing patients with Alzheimer’s disease: a scoping review
Noda, K., Kageyama, I., Kobayashi, Y., Lim, Y., Sengoku, S., & Kodama, K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104363 · Cited by 7
Aguila, A. L., Lorenzini, L., Janahi, M., Barkhof, F., & Altmann, A. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01753-3 · Cited by 11
Guo, H.-H., Liang, D.-X., Zhang, Q., Fu, Y., Huang, L.-Y., Sheng, Z.-H., Tan, L., & Wang, Z.-T. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03389-1 · Cited by 14
Advancements and challenges in using AI for biomarker detection in early Alzheimer’s disease
Beheshti, I., Albensi, B. C., Freitas, A. A., & Ghafourian, T. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104415 · Cited by 9
Zhang, Q., Yu, L.-K., Zhang, X.-Y., Wu, Y., Zhang, H., Wu, J.-L., Yao, Z., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251352411 · Cited by 7
miR-423-5p and miR-92a-3p in Alzheimer’s disease: relationship with pathology and cognition
Han, S., Park, Y. H., Pyun, J., Bice, P. J., Kim, S., Saykin, A. J., & Nho, K. T. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1637368 · Cited by 11
“…diagnosed with probable AD and cognitively normal (CN) were followed up prospectively with clinical data, neuroimaging studies, and biological samples for molecular biomarker measurements, as previously described (Aisen et al., 2010; Petersen et al., 2010; Aisen et al., 2015; Weiner et al., 2017).”
Dong, X., Li, Y., Hao, J., Zhou, P., Yang, C., Ai, Y., He, M. Y., Zhang, W., & Hu, H. (2025) · BMC Neurology · doi:10.1186/s12883-025-04404-0 · Cited by 8
Graph neural networks for fMRI functional brain networks: A survey
Tang, J., Zhu, T., Zhou, W., & Zhao, W. (2025) · Neural Networks · doi:10.1016/j.neunet.2025.108137 · Cited by 7
The Genetic Architecture of the Human Corpus Callosum and its Subregions
Bhatt, R. R., Gadewar, S. P., Shetty, A., Gari, I. B., Haddad, E., Javid, S., Ramesh, A., Nourollahimoghadam, E., Zhu, A. H., de Leeuw, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64791-3 · Cited by 7
Bayahya, A. Y., Banjar, H. R., Talabay, O., & Alamri, S. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-27914-w · Cited by 9
Abushakra, S. R., Doraiswamy, P. M., Hey, J. A., Tosun, D., Barkhof, F., Barakos, J. A., Petrella, J. R., Kesslak, J. P., Power, A., Sabbagh, M. N., et al. (2025) · CNS Drugs · doi:10.1007/s40263-025-01251-y · Cited by 11
Kang, W., Li, B., Jiskoot, L. C., Deyn, P. P. D., Biessels, G. J., Koek, H. L., Claassen, J. A. H. R., Middelkoop, H. A. M., van der Flier, W. M., Jansen, W. J., et al. (2026) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2026.102722 · Cited by 8
Language patterns in Japanese patients with Alzheimer disease: A machine learning approach
Momota, Y., Liang, K., Horigome, T., Kitazawa, M., Eguchi, Y., Takamiya, A., Goto, A., Mimura, M., & Kishimoto, T. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13526 · Cited by 10
Cheng, J., Ji, X., He, L., Zhang, Y., Xiao, T., Geng, Q., Wang, Z., Qi, S., Zhou, F., & Zhan, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010028 · Cited by 7
Boz, H. E., Koçoğlu, K., Akkoyun, M., Tüfekçi, I. Y., Ekin, M., & Akdal, G. (2023) · Brain and Behavior · doi:10.1002/brb3.3232 · Cited by 9
Uncovering Structural-Functional Coupling Alterations for Neurodegenerative Diseases
Dan, T., Kim, M., Kim, W. H., et al. (2023) · Lecture notes in computer science · doi:10.1007/978-3-031-43898-1_9 · Cited by 7
Levine, T. F., Dessenberger, S. J., Allison, S. L., Head, D. M., & Initiative, T. A. D. N. (2023) · Journal of the International Neuropsychological Society · doi:10.1017/s135561772300070x · Cited by 7
Thomson, D., Rosenich, E., Maruff, P. T., Lim, Y. Y., & Initiative, A. D. N. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae014 · Cited by 7
“Diagnoses of MCI and AD required scores of ≤ 8 (i.e., 16 years of education), ≤ 4 (8–15 years of education), or ≤ 2 (i.e., 0–7 years of education) on the Logical Memory II (Delayed Recall) subscale (Petersen et al., 2010).”
Deenadayalan, T., & Shantharajah, S. P. (2024) · Journal of Integrated Science and Technology · doi:10.62110/sciencein.jist.2024.v12.803 · Cited by 7
Disease‐driven domain generalization for neuroimaging‐based assessment of Alzheimer's disease
Lteif, D., Sreerama, S., Bargal, S. A., Plummer, B. A., Au, R., & Kolachalama, V. B. (2024) · Human Brain Mapping · doi:10.1002/hbm.26707 · Cited by 8
Scalp surface estimation and head registration using sparse sampling and 3D statistical models
Schlesinger, O., Kundu, R., Isaev, D., Choi, J. Y., Goetz, S. M., Turner, D. A., Sapiro, G., Peterchev, A. V., & Martino, J. M. D. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108689 · Cited by 8
Liu, X., Yu, G.-X., Xue, M., Huang, L., Fu, Y., Wang, Z.-T., Tan, L., & Ou, Y. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01550-4 · Cited by 8
Shastry, K. A. (2024) · SN Computer Science · doi:10.1007/s42979-024-03284-4 · Cited by 7
Tau-network mapping of domain-specific cognitive impairment in Alzheimer’s disease
Luan, Y., Rubinski, A., Biel, D., Svaldi, D. O., Higgins, I. A., Shcherbinin, S., Pontecorvo, M. J., Franzmeier, N., & Ewers, M. (2024) · NeuroImage Clinical · doi:10.1016/j.nicl.2024.103699 · Cited by 11
“The clinical diagnostic criteria in ADNI were described previously (Petersen et al., 2010).”
MethodLeveraging Multimodal Models for Enhanced Neuroimaging Diagnostics in Alzheimer’s Disease
Chiumento, F., & Liu, M. (2024) · IEEE International Conference on Big Data (BigData) · doi:10.1109/bigdata62323.2024.10825149 · Cited by 7
“In the field of Alzheimer’s disease, notable datasets include the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [20], Open Access Series of Imaging Studies (OASIS) [21], and Australian Imaging, Biomarkers and Lifestyle (AIBL) [22].”
Cross‐Dataset Evaluation of Dementia Longitudinal Progression Prediction Models
Zhang, C., An, L., Wulan, N., Nguyen, K., Orbán, C., Chen, P., Chen, C., Zhou, J. H., Liu, K., Yeo, B. T. T., et al. (2025) · Human Brain Mapping · doi:10.1002/hbm.70280 · Cited by 9
Genetic epistasis regulates amyloid deposition in resilient aging
Felsky, D., Xu, J., Chibnik, L. B., Schneider, J. A., Knight, J., Kennedy, J. L., Bennett, D. A., Jager, P. L. D., & Voineskos, A. N. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.027 · Cited by 7
Vito, A. N. D., Calamia, M. R., Weitzner, D. S., Bernstein, J. P. K., & Initiative, A. D. N. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4963 · Cited by 7
“5; and (4) general cognitive and functional performance such that dementia could not be diagnosed at baseline.(30)”
BackgroundEffects of CD33 Variants on Neuroimaging Biomarkers in Non-Demented Elders
Wang, Y., Initiative, A. D. N., Wan, Y., Wang, H.-F., Tan, C., Li, J., Yu, J., & Tan, L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181062 · Cited by 7
Tian, M.-L., Ni, X.-N., Li, J., Tan, C., Cao, X., Tan, L., & Initiative, A. D. N. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00742 · Cited by 6
Donohue, M., Model, F., Delmar, P., Volye, N., Liu‐Seifert, H., Rafii, M. S., Aisen, P. S. S., & Initiative, A. D. N. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12058 · Cited by 7
“13 The inclusion and exclusion criteria, schedule of assessments,andotherdetailscanbefoundatadni.loni.usc.edu.”
Self-citationYashin, A. I., Wu, D., Arbeev, K. G., Bagley, O., Akushevich, I. V., Duan, M., Yashkin, A. P., & Ukraintseva, S. V. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111477 · Cited by 7
Ekblad, L. L., Visser, P. J., & Tijms, B. M. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.07.003 · Cited by 7
A Penalty Approach for Normalizing Feature Distributions to Build Confounder-Free Models
Vento, A., Zhao, Q., Paul, R. H., Pohl, K. M., & Adeli, E. (2022) · Lecture notes in computer science · doi:10.1007/978-3-031-16437-8_37 · Cited by 7
Qiu, T., Zeng, Q., Zhang, Y., Luo, X., Xu, X., Li, X., Shen, Z., Li, K., Wang, C., Huang, P., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15860 · Cited by 7
Xiong, C., McCue, L. M., Buckles, V., Grant, E., Agboola, F., Coble, D. W., Bateman, R. J., Fagan, A. M., Benzinger, T. L. S., Hassenstab, J. J., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12912 · Cited by 7
Do preclinical Alzheimer's disease criteria work?
Petersen, R. C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70217-5 · Cited by 7
Self-citationRETRACTED ARTICLE: A voxel based morphometry approach for identifying Alzheimer from MRI images
Saravanakumar, S., & Thangaraj, P. (2018) · Cluster Computing · doi:10.1007/s10586-018-2236-6 · Cited by 7
RetractedDepression, Dementia, and Pseudodementia
Pozzoli, S., Carlo, V. D., & Madonna, D. (2018) · Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches · doi:10.1007/978-3-319-91557-9_10 · Cited by 2
Thermodynamic edge entropy in Alzheimer’s disease
Wang, J., Huo, J., & Zhang, L. (2019) · Pattern Recognition Letters · doi:10.1016/j.patrec.2019.06.026 · Cited by 7
Yoon, H., Kim, S.-G., Kim, S. H., Choo, I. H., Park, S. H., Seo, E. H., & Initiative, A. D. N. (2019) · Yonsei Medical Journal · doi:10.3349/ymj.2019.60.10.935 · Cited by 8
Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer’s disease
Ou, Y., Hu, H., Wang, Z.-T., Xu, W., Tan, L., Yu, J., & Initiative, A. D. N. (2019) · Brain Science Advances · doi:10.1177/2096595820902582 · Cited by 10
Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
Guo, Y., Li, H., Tan, L., Chen, S., Yang, Y., Ma, Y., Zuo, C., Dong, Q., Tan, L., Yu, J., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51196 · Cited by 7
“edu).(23,24) The ADNI was launched in 2003 as a public–private partnership with the primary goal of testing the effectiveness of integrating neuroimaging, clinical, biological, and neuropsychological markers in measuring the progression of mild cognitive impairment (MCI) and early AD.”
BackgroundChange point analyses in prodromal Alzheimer’s disease
Bachman, A. H., & Ardekani, B. A. (2020) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2020.100028 · Cited by 7
Kinoshita, K., Otsuka, R., Takada, M., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.25 · Cited by 7
Thomas, K. R., Weigand, A. J., Cota, I. H., Edmonds, E. C., Wierenga, C. E., Bondi, M. W., Bangen, K. J., & Initiative, A. D. N. (2021) · Brain Imaging and Behavior · doi:10.1007/s11682-021-00495-8 · Cited by 8
Wang, Z., Initiative, A. D. N., Wang, J., Liu, N., Liu, C., Li, X., Dong, L., Zhang, R., Mao, C., Duan, Z., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220502 · Cited by 7
Neuropathology of mild cognitive impairment
Takao, M. (2012) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.52.851 · Cited by 7
Patient Similarity Analysis with Longitudinal Health DataPreprint
Allam, A., Dittberner, M., Sintsova, A., Brodbeck, D., & Krauthammer, M. O. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2005.06630 · Cited by 7
Mandal, P. K., Jindal, K., Maroon, J. C., Chhikara, R. R., Samkaria, A., Joshi, M., Roy, S., & Arora, Y. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00265 · Cited by 7
Wojtas, A., Rathore, S., Dammer, E. B., Yu, L., Seifar, F., Gadhavi, J. D., Shantaraman, A., Duong, D. M., Wu, F., Liu, Y., et al. (2025) · SSRN Electronic Journal · doi:10.1101/2025.10.08.25337413 · Cited by 9
Metadata
- Authors
- Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Weiner, M. W.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Neurology
- Published
- 2010-01-19
- Volume
- 74
- Issue
- 3
- Pages
- 201-209
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2809036
- OpenAlex
- W2122328291
- Cited by
- 2,572
- References
- 27
- Citations by year
- 2026: 312 · 2025: 391 · 2024: 327 · 2023: 254 · 2022: 233 · 2021: 209 · 2020: 182 · 2019: 121 · 2018: 85 · 2017: 67 · 2016: 71 · 2015: 66 · 2014: 45 · 2013: 63 · 2012: 59
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- Alzheimer's Disease Neuroimaging Initiative (AG024904)
- National Institutes of Health (5r01ag027984-03, 5r01ag030048-05, n01mh22005-16-0-1, 5r01dk075128-05, 5u01ag006786-38, 5r01mh083552-05, 5r01ca104573-05, 5p30ag010124-30, 5p01ag009215-20, 5r01ag011378-25, 5p41rr023953-04, 5u01ag024904-10, 5u01ag029213-05, 5r01ag016381-08, 5r01eb006266-04, 5r01ag010897-27, AG024904, 5p01ag019724-23, 5p30ca093373-23, 5p50ag016574-20)
- National Institute on Aging (AG027984, U01-AG-024904, R01AG11378, P30AG010129, U19 AG010483, U01‐AG10483, R01-AG030048, P50‐AG16574, P01 & AG019724, U01AG06786, P50-AG23501, RC1AG035427, AG 010483, R01AG031224, AG031224, P01 AG 17586-10, 1 U01 AG024904, AG 024904, UO1AG029213-01, P30AG036468, 2 P50 AG016570, 1 U01 AG 024904-05, P30 AG 10124-18, R01 AG031252, P01AG017586, U01AG010483, 1 U01 AG24904, 1P01 AG-19724-07, R01AG027859, P50AG023501, AG027859, P01 AG012435, AG-11378, 2P50AG005133, RC2AG036535, P01-AG19724, P01 AG 09215-20, R01-AG 10897, 2P30AG10129, R01 AG029672, R01 AG16381)
- National Heart, Lung, and Blood Institute (HL-095089, R01HL095089)
- National Institute of Mental Health (U01MH083506, MH 22005, MH062512, MH083506, R01MH079752, R01MH069433, MH083552, MH079752, R01 MH069259, 5 R01 MH071940, MH069433, R01MH072641, P30MH062512)
- National Institute on Drug Abuse (1 R01 DA017830)
- National Cancer Institute (2 P30 CA93373, CA104573)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK075128)
- National Institute of Neurological Disorders and Stroke (1 R01 NS050792, RL1NS062412, P50NS053488, 1 R01 NS049194, RC2NS069368, R01NS031966)
- National Institute of Biomedical Imaging and Bioengineering (1 U54 EB05149, 1 R01 EB 006266-01, U54EB005149, P01EB001955, 5R01EB002138-07)
- U.S. National Library of Medicine (2 R01LM005639)
- National Center for Research Resources (5 P41 RR013642, P41 RR-023953, U24RR021760, U54RR021813, R24 RR021382, R24 RR021992, KL2RR024144)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD050735, 1R01 HD053893-01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, neuroimaging biomarkers, cerebrospinal fluid biomarkers, amyloid-beta 42, longitudinal cognitive change, normal aging, memory impairment, ADAS-Cog
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Diagnostic Imaging, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
